Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Basic & Translational Research, Retina

Sugar Rush

Retinitis pigmentosa (RP) comes in many forms. It can be inherited in autosomal dominant, autosomal recessive, X-linked and even maternally (mitochondrial) forms. When it’s combined with deafness, it’s called Usher syndrome; when the mitochondria are involved, it’s Kearns-Sayre syndrome; hypogonadism and developmental delay, it’s Bardet-Biedl syndrome. The list goes on, but the point is today, 64 genes have been identified that can cause RP when mutated. This poses a bit of a challenge when trying to take a genetic approach to treating it. But what if you could treat RP at a point downstream of these receptors, bypassing the entire problem?

Credit: The Jonas Children's Vision Care, Columbia University Medical Centre. Figure 1. Image of retina from right eye of a patient with retinitis pigmentosa due to phosphodiesterase deficiency. Intraretinal pigments (pink) are seen in areas of photoreceptor loss.

Photoreceptors are among the most metabolically active cells in the body – they convert between 80–96 percent of glucose into lactic acid via aerobic glycolysis. Under normal conditions, the outer segments of photoreceptors are continuously regenerated in a process that requires NADPH from the pentose phosphate pathway (PPP) to generate phospholipids. Rods shuttle glucose into the PPP to synthesize new membranes and generate new outer segments. Now remember that in darkness, rods are continuously depolarized and have a phenomenal consumption of glucose – and one of the first manifestations of RP in people with the disease is dysgenesis of rod outer segments. All of this suggests that the cell death seen in RP (Figure 1) is a consequence of metabolic dysfunction.

It was this that made a team of researchers from the US and China hypothesize that they might be able to rescue the degenerative phenotype by inhibiting a transcription factor gene called Sirt6, which acts as a repressor of glycolytic flux. To find out, they used a murine mouse model of severe RP: Pde6-/- mutant mice, which exhibit near complete photoreceptor loss by two months. Genetically disrupting Sirt6 resulted in rod cells remaining in a permanent state of glycolysis – and improved rod and cone health, with photoreceptors surviving in these mice far longer than in untreated control mice (although eventually, photoreceptor death still occurred).

“Our study shows that precision metabolic reprogramming can improve the survival and function of affected rods and cones in at least one type of RP. Since many, if not most, forms of the disorder have the same metabolic error, precision reprogramming could conceivably be applied to a wide range of RP patients,” says Tsang. “Our next challenge is to figure out how to extend the therapeutic effect of Sirt6 inhibition,” he adds.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. L Zhang et al., “Reprogramming metabolism by targeting sirtuin 6 attenuates retinal degeneration”, J Clin Invest, [Epub ahead of print] (2016). PMID: 27841758.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register